Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

654 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.
Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Wong R, et al. Among authors: anagnostopoulos a. Blood. 2003 Oct 15;102(8):3052-9. doi: 10.1182/blood-2003-03-0855. Epub 2003 Jul 3. Blood. 2003. PMID: 12842990 Free article.
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S. de Lima M, et al. Among authors: anagnostopoulos a. Blood. 2004 Aug 1;104(3):865-72. doi: 10.1182/blood-2003-11-3750. Epub 2004 Apr 15. Blood. 2004. PMID: 15090449 Free article.
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Oran B, et al. Among authors: anagnostopoulos a. Biol Blood Marrow Transplant. 2007 Apr;13(4):454-62. doi: 10.1016/j.bbmt.2006.11.024. Epub 2007 Feb 8. Biol Blood Marrow Transplant. 2007. PMID: 17382251 Free PMC article. Clinical Trial.
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri IF, Anderlini P, Hosing C, Alousi A, Champlin RE, de Lima M. Kebriaei P, et al. Among authors: anagnostopoulos a. Blood. 2007 Nov 1;110(9):3456-62. doi: 10.1182/blood-2007-04-085969. Epub 2007 Jul 25. Blood. 2007. PMID: 17652620 Free article.
Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.
Ueno NT, Anagnostopoulos A, Rondón G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M, Zaritskey AY. Ueno NT, et al. Among authors: anagnostopoulos a. Br J Haematol. 2002 Oct;119(1):131-4. doi: 10.1046/j.1365-2141.2002.03771.x. Br J Haematol. 2002. PMID: 12358917 Free article. Review.
Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A, Hari PN, Pérez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA. Anagnostopoulos A, et al. Biol Blood Marrow Transplant. 2006 Aug;12(8):845-54. doi: 10.1016/j.bbmt.2006.04.010. Biol Blood Marrow Transplant. 2006. PMID: 16864055 Free article.
654 results